SESSION IX: INDOLENT B-CELL LYMPHOMA 

Session Chairs: Lorenzo Falchi, MD and Laurie H. Sehn, MD, MPH

Follicular Lymphoma: Does The Choice of Frontline Treatment Matter? | Christopher R. Flowers, MD, MS | MD Anderson Cancer Center, Houston, Texas, USA

Follicular Lymphoma, When to Use a Bispecific Antibody and Which One? | Laurie H. Sehn, MD, MPH | BC Cancer Agency, Vancouver, Canada

Novel Immunotherapy Combinations in Indolent Lymphoma | Lorenzo Falchi, MD | Memorial Sloan Kettering Cancer Center, New York, New York, USA

Relapsed/Refractory Indolent Lymphoma, Options Beyond Immunotherapy | Pier Luigi Zinzani, MD, PhD | University of Bologna, Bologna, Italy

Oral Abstract | IBCL-1494: MorningSun: Open-Label Phase 2 Trial of the Efficacy and Safety of Subcutaneous Mosunetuzumab As Frontline Treatment in Symptomatic Patients With Marginal Zone Lymphoma (MZL) | Tara Graff, DO | Mission Cancer and Blood, Des Moines, Idaho, USA